Advanced investigations are in action worldwide to find medications with improved safety profiles. Natural resources are essential in the creation of innovative treatments and drugs that have fewer side effects. The essential oil (EO) of lavender (Lavandula officinalis) is well-known in alternative and complementary therapies for its use as wound-healing and antimicrobial ingredients. However, the exact pharmacological and anti-inflammatory aspects of naturally produced lavender essential oil (LEO) compounds are still unknown. As a consequence, it is essential to explain LEO drug molecular docking experiments with cyclo-oxygenase enzymes (COX-1 and COX-2). An attempt was developed in this study to discover the anti-inflammatory activity of LEO bioactive components. The online DockThor server was used for in silico molecule docking simulation. Interaction studies of LEO compound binding poses with COX were performed to get an understanding of the interacting amino acids and their inter-molecular bondings. Based on physicochemical attributes and toxicity, the docked compounds with the greatest binding affinities were also investigated for drug similarity utilizing the admetSAR tool and PASS platforms. Molecular docking studies exploring the bioactive principle targeted action revealed that electrostatic interactions and H-bonds make the main causative factor in inter-molecular connections associated with anti-inflammatory action. Seven top-ranked compounds were selected by virtual screening. Molecular docking revealed that limonene has the highest negative binding affinity (−8.536 kcal/mol) in complex with COX-1, followed by α-terpineol (−8.535 kcal/mol) and p-cymene (−8.515 kcal/mol), while two approved anti-inflammatory drugs (celecoxib and betamethasone) produced −8.191 and −8.041 kcal/mol respectively. Similarly, these terpenes can be documented as promising drug candidates based on qualifying Lipinski's rule five. The selected terpenes showed excellent drug-like properties and a percentage of human oral absorption. Besides, it was found to be safe for the human body in toxicological risk assessment. This work gives insight into the anti-inflammatory mechanism of action of LEO terpenes. LEO drugs' pharmacokinetic data and molecular docking patterns may open the way for the development of new COX inhibitors with anti-inflammatory capability and improved pharmacokinetic and pharmacodynamic properties.
Citation: Bouchra Sarah Boukhatem, Abd-Elmouneim Belhadj. In silico anti-inflammatory activity of lavender (Lavandula officinalis) essential oil bioactive compounds: Molecular docking analysis of COX-1 and COX-2, and ADMET prediction[J]. AIMS Allergy and Immunology, 2023, 7(2): 132-153. doi: 10.3934/Allergy.2023009
[1] | Chun He, James C.L. Chow . Gold nanoparticle DNA damage in radiotherapy: A Monte Carlo study. AIMS Bioengineering, 2016, 3(3): 352-361. doi: 10.3934/bioeng.2016.3.352 |
[2] | Dewmini Mututantri-Bastiyange, James C. L. Chow . Imaging dose of cone-beam computed tomography in nanoparticle-enhanced image-guided radiotherapy: A Monte Carlo phantom study. AIMS Bioengineering, 2020, 7(1): 1-11. doi: 10.3934/bioeng.2020001 |
[3] | Megha Sharma, James C. L. Chow . Skin dose enhancement from the application of skin-care creams using FF and FFF photon beams in radiotherapy: A Monte Carlo phantom evaluation. AIMS Bioengineering, 2020, 7(2): 82-90. doi: 10.3934/bioeng.2020008 |
[4] | Abdulmajeed Alsufyani . Performance comparison of deep learning models for MRI-based brain tumor detection. AIMS Bioengineering, 2025, 12(1): 1-21. doi: 10.3934/bioeng.2025001 |
[5] | José Luis Calvo-Guirado, Marta Belén Cabo-Pastor, Félix de Carlos-Villafranca, Nuria García-Carrillo, Manuel Fernández-Domínguez, Francisco Martínez Martínez . Micro-CT evaluation of bone grow concept of an implant with microstructured backtaper crestally and sub-crestally placed. Preliminary study in New Zealand rabbits tibia at one month. AIMS Bioengineering, 2023, 10(4): 406-420. doi: 10.3934/bioeng.2023024 |
[6] | N. Supraja, T.N.V.K.V. Prasad, M. Soundariya, R. Babujanarthanam . Synthesis, characterization and dose dependent antimicrobial and anti-cancerous activity of phycogenic silver nanoparticles against human hepatic carcinoma (HepG2) cell line. AIMS Bioengineering, 2016, 3(4): 425-440. doi: 10.3934/bioeng.2016.4.425 |
[7] | Sarbaz H. A. Khoshnaw, Azhi Sabir Mohammed . Computational simulations of the effects of social distancing interventions on the COVID-19 pandemic. AIMS Bioengineering, 2022, 9(3): 239-251. doi: 10.3934/bioeng.2022016 |
[8] | Kristen K. Comfort . The rise of nanotoxicology: A successful collaboration between engineering and biology. AIMS Bioengineering, 2016, 3(3): 230-244. doi: 10.3934/bioeng.2016.3.230 |
[9] | Xiang-Xiang Guan, Xiao-Juan Zhu, Zhao-Hui Deng, Yu-Rong Zeng, Jie-Ru Liu, Jiang-Hua Li . The association between nicotinamide N-methyltransferase gene polymorphisms and primary hypertension in Chinese Han Population. AIMS Bioengineering, 2021, 8(2): 130-139. doi: 10.3934/bioeng.2021012 |
[10] | Jose Luis Calvo-Guirado, Nuria García Carrillo, Félix de Carlos-Villafranca, Miguel Angel Garces-Villala, Lanka Mahesh, Juan Carlos Ibanez, Francisco Martinez-Martinez . A micro-CT evaluation of bone density around two different types of surfaces on one-piece fixo implants with early loading-an experimental study in dogs at 3 months. AIMS Bioengineering, 2022, 9(4): 383-399. doi: 10.3934/bioeng.2022028 |
Advanced investigations are in action worldwide to find medications with improved safety profiles. Natural resources are essential in the creation of innovative treatments and drugs that have fewer side effects. The essential oil (EO) of lavender (Lavandula officinalis) is well-known in alternative and complementary therapies for its use as wound-healing and antimicrobial ingredients. However, the exact pharmacological and anti-inflammatory aspects of naturally produced lavender essential oil (LEO) compounds are still unknown. As a consequence, it is essential to explain LEO drug molecular docking experiments with cyclo-oxygenase enzymes (COX-1 and COX-2). An attempt was developed in this study to discover the anti-inflammatory activity of LEO bioactive components. The online DockThor server was used for in silico molecule docking simulation. Interaction studies of LEO compound binding poses with COX were performed to get an understanding of the interacting amino acids and their inter-molecular bondings. Based on physicochemical attributes and toxicity, the docked compounds with the greatest binding affinities were also investigated for drug similarity utilizing the admetSAR tool and PASS platforms. Molecular docking studies exploring the bioactive principle targeted action revealed that electrostatic interactions and H-bonds make the main causative factor in inter-molecular connections associated with anti-inflammatory action. Seven top-ranked compounds were selected by virtual screening. Molecular docking revealed that limonene has the highest negative binding affinity (−8.536 kcal/mol) in complex with COX-1, followed by α-terpineol (−8.535 kcal/mol) and p-cymene (−8.515 kcal/mol), while two approved anti-inflammatory drugs (celecoxib and betamethasone) produced −8.191 and −8.041 kcal/mol respectively. Similarly, these terpenes can be documented as promising drug candidates based on qualifying Lipinski's rule five. The selected terpenes showed excellent drug-like properties and a percentage of human oral absorption. Besides, it was found to be safe for the human body in toxicological risk assessment. This work gives insight into the anti-inflammatory mechanism of action of LEO terpenes. LEO drugs' pharmacokinetic data and molecular docking patterns may open the way for the development of new COX inhibitors with anti-inflammatory capability and improved pharmacokinetic and pharmacodynamic properties.
We consider a singular no-sign obstacle problem of the type
{div(xa1∇u)=xa1f(x)χ{u≠0}in B+1,u=0on B1∩{x1=0}, | (1.1) |
where a>1, χD is the characteristic function of D, B1⊂Rn is the unit ball and B+1=B1∩{x1>0}. The equation is considered in the weak form,
∫B+1xa1∇u∇φdx=∫B+1xa1f(x)φχ{u≠0}dx, |
for all φ∈W1,20(B+1). This problem, when the non-negativity assumption u≥0 is imposed, is already studied in [9]. The above no-sign problem, as a general semilinear PDE with non-monotone r.h.s., introduces certain difficulties and to some extent some challenges. To explain this we shall give a very short review of the existing results and methods for similar type of problems (see also the book [6] and Caffarelli's review of the classical obstacle problem [2]). The general methodology of approaching such problems lies in using the so-called ACF-monotonicity formula (see [8]) or alternatively using John Andersson's dichotomy (see [1] or [3]). Although there are still some chances that both these methods will work for our problem above, we shall introduce a third method here which relies on a softer version of a monotonicity formula (which has a wider applicability) in combination with some elaborated analysis. We refer to this as a Weiss-type monotonicity formula, see (2.1) below.
For clarity of exposition we shall introduce some notations and definitions here that are used frequently in the paper. Throughout this paper, Rn will be equipped with the Euclidean inner product x⋅y and the induced norm |x|, Br(x0) will denote the open n-dimensional ball of center x0, radius r with the boundary ∂Br(x0). In addition, Br=Br(0) and ∂Br=∂Br(0). Rn+ stands for half space {x∈Rn:x1>0} as well as B+r=Br∩Rn+. Moreover, in the text we use the n-dimensional Hausdorff measure Hn. For a multi-index μ=(μ1,⋯,μn)∈Zn+, we denote the partial derivative with ∂μu=∂μ1x1⋯∂μnxnu and |μ|1=μ1+⋯+μn.
For a domain Ω⊂Rn+ and 1≤p<∞, we use the notation Lp(Ω) and Wm,p(Ω) as the standard spaces. However, we need some new notation for the weighted spaces
Lp(Ω;xθ1):={u:∫Ωxθ1|u(x)|pdx<∞}, |
where θ∈R. For m∈N, we define the weighted Sobolev space Wm,p(Ω;xθ1) as the closure of C∞(¯Ω) with the following norm,
‖u‖Wm,p(Ω;xθ1):=‖u‖Lp(Ω;xθ1)+‖x1Du‖Lp(Ω;xθ1)+⋯+‖xm1Dmu‖Lp(Ω;xθ1). |
It is noteworthy that for θ=0, we have Lp(Ω;1)=Lp(Ω) but Wm,p(Ω;1)⊋Wm,p(Ω). Generally, the trace operator has no sense for θ>−1, while functions in W1,p(Ω;xθ1) have zero traces on {x1=0} for θ≤−1. (Theorem 6 in [7]).
We consider u∈W1,p(B+1,xθ1) for some θ<−n and n<p to be a weak solution of (1.1). This condition provides the continuity of x(θ+n)/p1u up to the boundary according to Sobolev embedding Theorem 3.1 in [5]. First, we prove the following a priori regularity result.
Proposition 1.1. (Appendix A) Let u∈W1,p(B+1,xθ1) be a solution of (1.1) for some θ<−n, n<p and f∈L∞(B+1). Then for each max{0,1+θ+np}<β<1 there exists C=C(β,n,a) such that for r≤1/2,
supB+r(x0)|xβ−11u|≤Cr2β, |
for all x0∈{x1=0}.
In Appendix A we will prove this proposition. Our main result in this paper concerns the optimal growth rate of solution u of (1.1) at touching free boundary points, which is stated in the following theorem.
Theorem 1.2. Suppose u∈W1,p(B+1,xθ1) is a solution of (1.1) for some θ<−n, n<p and x0∈∂{u=0}∩{x1=0}∩B+1/4. Moreover, if f∈Cα(¯B+1) for some α∈(0,1), then
|u(x)|≤Cx21((|x−x0|+x1x1)(n+a+4)/2+1), |
for a universal constant C=C(a,n,[f]0,α).
Our main tool in proving optimal decay for solutions from the free boundary points is Weiss-monotonicity formula, combined with some elaborated techniques. We define the balanced energy functional
Φx0(r,u)=r−n−2−a∫B+r(x0)(xa1|∇u|2+2xa1f(x0)u)dx−2r−n−3−a∫∂Br(x0)∩Rn+xa1u2dHn−1. | (2.1) |
Considering the scaling ur,x0=ur(x)=u(rx+x0)r2, Φx0(r,u)=Φ0(1,ur). In what follows we prove almost-monotonicity of the energy.
Lemma 2.1 (Almost-Monotonicity Formula). Let u solve (1.1) and be as in Proposition 1.1 and assume that ∇u(x0)=0 for some x0∈{x1=0} and f∈Cα(¯B+1) for some α∈(0,1). Then u satisfies, for r≤r0 such that B+r0(x0)⊆B+1,
ddrΦx0(r,u)≥2r∫∂B1∩Rn+xa1(∂rur)2dHn−1−Crα+β−2, |
where C depends only on ‖f‖Cα(¯B+1) and the constant C(β,n,a) in Proposition 1.1.
Proof. Let ur(x):=u(rx+x0)r2, then
=12ddrΦx0(r,u)=12ddr[∫B+1(xa1|∇ur|2+2xa1f(x0)ur)dx−2∫∂B1∩Rn+xa1u2rdHn−1]=12[∫B+1(2xa1∇ur⋅∇∂rur+2xa1f(x0)∂rur)dx−4∫∂B1∩Rn+xa1ur∂rurdHn−1]=∫B+1div(xa1∂rur∇ur)−∂rurdiv(xa1∇ur)+xa1f(x0)∂rurdx−2∫∂B1∩Rn+xa1ur∂rurdHn−1=∫B+1(f(x0)−f(rx+x0)χ{ur≠0})xa1∂rurdx+∫∂B+1xa1∂rur∇ur⋅νdHn−1−2∫∂B1∩Rn+xa1ur∂rurdHn−1=∫B+1(f(x0)−f(rx+x0)χ{ur≠0})xa1∂rurdx+r∫∂B1∩Rn+xa1(∂rur)2dHn−1=∫B+1(f(x0)−f(rx+x0))χ{ur≠0}xa1∂rurdx+f(x0)∫B+1∩{ur=0}xa1∂rurdx+r∫∂B1∩Rn+xa1(∂rur)2dHn−1. |
Note that the second integral
∫B+1∩{ur=0}xa1∂rurdx=0 |
as |{ur=0∧∇ur≠0}|=0 and ∂rur=0 on {ur=0∧∇ur=0}. Since |∂rur|≤Crβ−2 we infer that
∫B+1(f(x0)−f(rx+x0))χ{ur≠0}xa1∂rurdx≥−Crα+β−2 |
and conclude that
12ddrΦx0(r,u)≥r∫∂B1∩Rn+xa1(∂rur)2dHn−1−Crα+β−2. |
Definition 2.2. Let HP2 stand for the class of all two-homogeneous functions P∈W1,2(B+1;xa−21) satisfying div(xa1∇P)=0 in Rn+ with boundary condition P=0 on x1=0. We also define the operator Π(v,r,x0) to be the projection of vr,x0 onto HP2 with respect to the inner product
⟨vw⟩=∫∂B1∩n+xa1vwdHn−1. |
We will use the following extension of [10,Lemma 4.1].
Lemma 2.3. Assume that div(xa1∇w)=0 in B+1 with boundary condition w=0 on x1=0, and w(0)=|∇w(0)|=0. Then
∫B+1xa1|∇w|2dx−2∫∂B1∩Rn+xa1w2dHn−1≥0, |
and equality implies that w∈HP2, i.e., it is homogeneous of degree two.
Proof. We define an extension of the Almgren frequency,
r↦N(w,r):=r∫B+rxa1|∇w|2dx∫∂B+rxa1w2dHn−1, |
12N′(w,r)N(w,r)=∫∂B+rxa1(∂νw)2dHn−1∫∂B+rxa1w∂νwdHn−1−∫∂B+rxa1w∂νwdHn−1∫∂B+rxa1w2dHn−1≥0. |
Moreover, if N(w,r)=κ for ρ<r<σ, it implies that w is homogeneous of degree κ in Bσ∖Bρ.
Now supposing towards a contradiction that N(w,s)<2 for some s∈(0,1], and defining wr(x):=w(rx)‖w(rx)‖L2(∂B+1,xb1), we infer from N(w,s)<2 that ∇wr is bounded in L2(B+1;xa1) and so ∇wrm⇀∇w0 weakly in L2(B+1;xa1) and wrm→w0 strongly in L2(∂B+1;xa1) as a sequence rm→0. Consequently, w0 satisfies div(xa1∇w0)=0 in B+1, w0(0)=|∇w0(0)|=0 and w0=0 on x1=0 as well as ‖w0‖L2(∂B+1;xa1)=1. Furthermore, for all r∈(0,1) we have
N(w0,r)=limrm→0N(wrm,r)=limrm→0N(w,rrm)=N(w,0+), |
and so w0 must be a homogeneous function of degree κ:=N(w,0+)<2. Note that for every multi-index μ∈{0}×Zn−1+, the higher order partial derivative ζ=∂μw0 satisfies the equation div(xa1∇ζ)=0 in Rn+. From the integrability and homogeneity we infer that ∂μw0≡0 for κ−|μ|1<−n2, otherwise
∫B+1|∂μw0|2dx=(∫10r2(κ−|μ|1)+n−1dr)∫∂B1∩Rn+|∂μw0|2dHn−1 |
can not be bounded. Thus x′↦w0(x1,x′) is a polynomial, and we can write w0(x1,x′)=xκ1p(x′x1). Consider the multi-index μ such that |μ|1=degp, so ∂μw0=xκ−|μ|11∂μp is a solution of div(xa1∇ζ)=0 in Rn+. Therefore, ∂μw0∈W1,2(B+1;xθ1) for −1<θ according to Proposition A.1, which implies that 2(κ−|μ|1)+θ>−1. So, degp<κ+θ+12.
Substituting w0(x)=xκ−11(αx1+ℓ⋅x′) for κ>1 in the equation and comparing with w0(0)=|∇w0(0)|=0 we arrive at the only nonzero possible case being κ+a=2, which contradicts a>1. The case κ<1 leads to degp=0 and w0(x)=αxκ1, which implies κ+a=1 and a contradiction to a>1.
Proposition 3.1. Let f∈Cα(¯B+1) and u be solution of (1.1) satisfying the condition in Proposition 1.1. Then the function
r↦r−n−3−a∫∂B+r(x0)xa1u2(x)dHn−1 |
is bounded on (0,1/8), uniformly in x0∈∂{u=0}∩{x1=0}∩B1/8.
Proof. Let us divide the proof into steps.
Step 1 We claim that there exists a constant C1<∞ such that for all x0∈∂{u=0}∩{x1=0}∩B1/8 and r≤1/8,
f(x0)∫B+1xa1ux0,r(x)dx≥−C1, |
where ux0,r:=u(rx+x0)r2. To prove this we observe that w:=ux0,r satisfies
div(xa1∇w)=xa1fr(x):=xa1f(x0+rx)χ{ux0,r≠0},in B+1. |
Moreover, for ϕ(ρ):=ρ−n−a+1∫∂B+ρxa1w(x)dHn−1 we have
ϕ′(ρ)=∫∂B+1xa1∇w(ρx)⋅xdHn−1=ρ−n−a+1∫B+ρdiv(xa1∇w(x))dx=ρ−n−a+1∫B+ρxa1fr(x)dx. |
If f(x0)≥18α[f]0,α then fr≥0 for r≤1/8. Therefore ϕ is increasing and ϕ(ρ)≥ϕ(0)=0 (recall that w(0)=0). Similarly, if f(x0)≤−18α[f]0,α, we obtain that ϕ(ρ)≤0. Therefore the claim is true for C1=0 in these cases.
In the case |f(x0)|≤18α[f]0,α, then |fr(x)|≤28α[f]0,α and then
|ϕ′(ρ)|≤21−3α[f]0,αρ−n−a+1∫B+ρxa1dx≤21−3α[f]0,αρ. |
So, |ϕ(ρ)|≤2−3α[f]0,αρ2 and
|f(x0)∫B+1xa1ux0,r(x)dx|=|f(x0)∫10ρn+a−1ϕ(ρ)dρ|≤2−6α[f]20,αn+a+2=:C1. |
Step 2 We claim that there exists a constant C2<∞ such that
distL2(∂B1∩Rn+;xa1)(ux0,r,HP2)≤C2, |
for every x0∈∂{u=0}∩{x1=0}∩B1/8, r≤1/8. Suppose towards a contradiction that this is not true, then there exists a sequence um, xm→ˉx and rm→0 such that
Mm=‖umxm,rm−Π(um,rm,xm)‖L2(∂B1∩Rn+;xa1)→∞,m→∞. |
Let um:=umxm,rm and pm=Π(um,rm,xm) and wm=um−pmMm. Then, since um(0)=|∇um(0)|=0 and by the monotonicity formula and the result of previous step, we find that
∫B+1xa1|∇wm|2dx−2∫∂B+1xa1w2mdHn−1=1M2m[Φxm(rm)−2∫B+1f(xm)xa1umdx]+1M2m∫∂B+1xa1(pm∇pm⋅ν−2um∇pm⋅ν−2p2m+4umpm)dHn−1≤1M2m(Φxm(rm)+2C1)≤1M2m(Φxm(12)+2C1)→0,m→∞. | (3.1) |
Passing to a subsequence such that ∇wm⇀∇w in L2(B+1;xa1) as m→∞, the compact embedding on the boundary implies that ‖w‖L2(∂B1∩Rn+;xa1)=1, and
∫B+1xa1|∇w|2dx≤2∫∂B1xa1w2dHn−1 | (3.2) |
and that
∫∂B1wpdHn−1=0,∀p∈HP2. | (3.3) |
Since div(xa1∇wm)=x1Mmf(xm+r⋅)χ{um≠0}, it follows that div(xa1∇w)=0 in B+1. Moreover, we obtain from Lp-theory that wm→w in C1,αloc(B+1) for each α∈(0,1) as m→∞. Consequently w(0)=|∇w(0)|=0. Thus we can apply Lemma 2.3 and obtain from (3.2) that w is homogeneous of degree 2, contradicting (3.3) and ‖w‖L2(∂B1)=1. This proves the claim.
Step 3 We will show that there exists constant C2 such that for all x0∈∂{u=0}∩{x1=0} satisfying
lim infr→0+|B+r(x0)∩{u=0}||B+r|=0, | (3.4) |
we have
Φx0(0+)−∫B+1xa1f(x0)ux0,rdx≥−C2rα|f(x0)|. |
In order to see this, we can observe that
∫B+1xa1f(x0)ux0,r(x)dx=f(x0)∫10∫10∂s[∫∂B+ρ(sx1)aux0,r(sx)dHn−1(x)]dsdρ=f(x0)∫10ρ∫10∫∂B+ρ(sx1)a∇ux0,r(sx)⋅νdHn−1dsdρ=f(x0)∫10ρ∫10s∫B+ρdiv((sx1)a∇ux0,r(sx))dxdsdρ=f(x0)∫10ρ∫10s∫B+ρ(sx1)af(rsx)χΩx0,r(sx)dxdsdρ=f(x0)2∫10ρ1+a+n∫10s1+a∫B+1xa1dxdsdρ+f(x0)∫10ρ1+a+n∫10s1+a∫B+1xa1(f(rsρx)−f(x0))dxdsdρ≤f(x0)2(n+a+2)(a+2)∫B+1xb1dx+C2rα|f(x0)|. |
Now by condition (3.4), consider a sequence rm→0 such that |B+rm(x0)∩{v=0}||B+rm|→0 and assume that ∇(ux0,rm−px0,rm)⇀∇w in L2(B+1;xa1) as m→∞. Observe now div(xa1w)=f(x0) in B+1 and by similar calculation as above we will have
∫B+1xa1f(x0)wdx=f(x0)2(n+a+2)(a+2)∫B+1xa1dx. |
On the other hand,
Φx0(0+)=limm→∞Φx0(rm)≥∫B+1(xa1|∇w|2+2f(x0)xa1w)dx−2∫∂B+1xa1w2dHn−1=∫B+1(−wdiv(xa1∇w)+2f(x0)xa1w)dx=∫B+1xa1f(x0)wdx=f(x0)2(n+a+2)(a+2)∫B+1xa1dx. |
Step 4 In this step, we prove the proposition for the points satisfying condition (3.4). For these points, we have
12∂r[∫∂B+1xa1u2x0,rdHn−1]=∫∂B+1xa1ux0,r∂rux0,rdHn−1=1r∫∂B+1xa1ux0,r(∇ux0,r⋅x−2ux0,r)dHn−1=1r∫B+1(xa1|∇ux0,r|2+ux0,rdiv(xa1∇ux0,r))dx−2r∫∂B+1xa1u2x0,rdHn−1=1r(Φx0(r)−2∫B+1f(x0)xa1ux0,r(x)dx+∫B+1xa1f(rx)ux0,r(x)dx)=1r(Φx0(r)−∫B+1f(x0)xa1ux0,rdx)+1r(∫B+1(f(rx)−f(x0))xa1ux0,r(x)dx)≥1r(Φx0(0+)−∫B+1f(x0)xa1ux0,rdx)−Crα+β−2−C3rα+β−2≥−C2rα−1−Crα+β−2−C3rα+β−2 |
Thus r↦∂r[∫∂B+1xa1u2x0,rdHn−1] is integrable and we obtain uniform boundedness of ∫∂B+1xa1u2x0,rdHn−1=r−n−3−b∫∂Br(x0)+xa1u2dHn−1 for all points with property (3.4). It follows that the boundedness holds uniformly on the closure of those points x0.
Step 5 We now consider the case
lim infr→0+|B+r(x0)∩{u=0}||B+r|>0. |
Let us assume towards a contradiction that there are sequences um, rm and xm such that and Mm=‖uxm,rm‖L2(∂B+1)→+∞ as m→∞. Setting wm=umxm,rmMm we obtain, as in Step 2, that a subsequence of wm converges weakly in W1,2(B+1;xa−21) to a function w, with ‖w‖L2(∂B+1;xa1)=1, w(0)=|∇w(0)|=0, div(xa1∇w)=0 and
∫B+1xa1|∇w|2dx≤2∫∂B+1xa1w2dHn−1. |
According to Lemma 2.3, w∈HP2. In addition we now know that
∫B+1χ{w=0}≥lim suprm→0+∫B+1χ{ux0,rm=0}>0. |
This however contradicts the analyticity of w inside B+1, knowing that ‖w‖L2(∂B1;xa1)=1.
Now we are ready to prove the main result of the article.
Proof of Theorem 1.2. From Theorem 8.17 in [4], we know that if div(b(x)∇w)=g such that 1≤b(x)≤5a, then there exists a universal constant C=C(a,n) such that
‖w‖L∞(BR/2)≤C(a,n)(R−n/2‖w‖L2(BR)+R2‖g‖L∞(BR)). |
Now for x0∈∂{u=0}∩{x1=0}∩B+1/8 and an arbitrary point y∈∂B+r(x0), we apply the above estimate for R=2δ/3, w=(δ/3)au and equation div(b(x)∇w)=xa1fχ{u≠0}, where δ=y1 and b(x)=xa1(δ/3)a. Note that 1≤b(x)≤5a in B2δ/3(y) and
|u(y)|≤C(a,n)((2δ/3)−n/2‖u‖L2(B2δ/3(y))+(2δ/3)25a‖f‖L∞(B2δ/3(y))). |
According to Proposition 3.1,
‖u‖2L2(B2δ/3(y))≤(3δ)a∫B2δ/3(y)xa1|u|2dx≤(3δ)a∫Br+2δ/3(x0)xa1|u|2dx≤C(3δ)a(r+2δ/3)n+a+4. |
Hence,
|u(y)|≤C(δ−(n+a)/2(r+δ)(n+a+4)/2+δ2)≤Cy21((r+y1y1)(n+a+4)/2+1). |
From this theorem it follows that solutions have quadratic growth inside cones.
Corollary 3.2. Suppose u is a solution of (1.1) satisfying the condition in Proposition 1.1 and x0∈∂{u=0}∩{x1=0}∩B+1/8. Then, for every constant τ>0,
supBr(x0)∩C|u|≤C((1τ+1)n+a+42+1)r2, |
where C:={x:x1≥τ|x−x0|}.
This paper was prepared while M. Fotouhi was visiting KTH Royal Institute of Technology. A. Minne was supported by the Knut and Alice Wallenberg Foundation. H. Shahgholian was supported by Swedish Research Council.
The authors declare no conflict of interest.
Let u be a solution of (1.1) for f∈L∞(B+1). We are going to show a priori regularity for solutions to (1.1). Consider the operator La,cu:=x21Δu+ax1∂1u−cu. The following proposition is the regularity result related to this operator which has been proven by Krylov [5,Theorem 2.7,Theorem 2.8].
Proposition A.1. i) For any a∈R,p>1 and θ∈R there exists a constant c0>0 such that for any c≥c0 the operator La,c is a bounded one-to-one operator from W2,p(Rn+;xθ1) onto Lp(Rn+;xθ1) and its inverse is also bounded, in particular for any u∈W2,p(Rn+;xθ1)
‖u‖W2,p(Rn+;xθ1)≤C‖La,cu‖Lp(Rn+;xθ1), |
where C is independent of u and c.
ii) The statement in i) is valid for the operator La,0 when −1<θ<a−2 and a>1 or either a−2<θ<−1 and a<1.
Now we can deduce a priori regularity result for u as follows.
Proof of Proposition 1.1. Notice that xβ−11u∈C(¯B+1) due to Sobolev embedding Theorem 3.1 in [5]. Then if the statement of proposition fails, there exists a sequence uj of solutions (1.1), xj∈{x1=0} and rj→0 such that
supB+r(xj)|xβ−11uj|≤jr1+β/2,∀r≥rj,supB+rj(xj)|xβ−11uj|=jr1+β/2j. |
In particular, the function ˜uj(x)=uj(xj+rjx)jr1+β/2j, satisfies
supB+R|xβ−11˜uj|≤R1+β/2,for 1≤R≤1rj, | (A.1) |
and with equality for R=1, along with
La,c0˜uj=r1−β/2jjf(xj+rjx)−c0˜uj, | (A.2) |
where c0 is defined in Proposition A.1. According to (A.1), the right hand side of (A.2) is uniformly bounded in Lp(B+R;xθ1) for p(β−1)−1<θ≤−1. From here and Proposition A.1 we conclude that {˜uj} is bounded in W2,p(B+R;xθ1) for some θ≤−1 and there is a convergent subsequence, tending to a function u0 with properties
supB+R|xβ−11u0|≤R1+β/2,∀R≥1,supB+1|xβ−11u0|=1,div(xa1∇u0)=0, | (A.3) |
as well as the condition θ≤−1 insures that the trace operator is well defined and u0 is zero on {x1=0}. The Liouville type theorem in [9,Lemma 20]) implies that
|D2u0(x0)|≤CR2supB+R(x0)|u0|≤C(R+|x0|)2−β/2R2→0. |
Therefore, u0 is a linear function, which contradicts (A.3).
[1] |
Bancos S, Bernard MP, Topham DJ, et al. (2009) Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol 258: 18-28. https://doi.org/10.1016/j.cellimm.2009.03.007 ![]() |
[2] | Day RO, Graham GG (2013) Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 346: f3195. https://doi.org/10.1007/978-3-0348-0620-6_52-2 |
[3] |
Wehling M (2014) Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 70: 1159-1172. https://doi.org/10.1007/s00228-014-1734-6 ![]() |
[4] |
Crofford LJ (2013) Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 15: 1-10. https://doi.org/10.1186/ar4174 ![]() |
[5] |
Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916. https://doi.org/10.1038/sj.onc.1203286 ![]() |
[6] |
Lucotti S, Cerutti C, Soyer M, et al. (2019) Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A 2. J Clin Invest 129: 1845-1862. https://doi.org/10.1172/JCI121985 ![]() |
[7] | Morita I (2002) Distinct functions of COX-1 and COX-2. Prostag Oth Lipid M 68: 165-175. https://doi.org/10.1016/S0090-6980(02)00029-1 |
[8] |
Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790-804. https://doi.org/10.1096/fj.03-0645rev ![]() |
[9] |
Dogné JM, Supuran CT, Pratico D (2005) Adverse cardiovascular effects of the coxibs. J Med Chem 48: 2251-2257. https://doi.org/10.1021/jm0402059 ![]() |
[10] |
Wallace JL (2001) Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Cl Ga 15: 691-703. https://doi.org/10.1053/bega.2001.0229 ![]() |
[11] |
Laine L (2003) Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manag 25: 32-40. https://doi.org/10.1016/S0885-3924(02)00629-2 ![]() |
[12] |
Gierse J, Nickols M, Leahy K, et al. (2008) Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol 588: 93-98. https://doi.org/10.1016/j.ejphar.2008.03.057 ![]() |
[13] |
Farzaneh V, Carvalho IS (2015) A review of the health benefit potentials of herbal plant infusions and their mechanism of actions. Ind Crop Prod 65: 247-258. https://doi.org/10.1016/j.indcrop.2014.10.057 ![]() |
[14] |
Reddy DN (2019) Essential oils extracted from medicinal plants and their applications. Natural Bio-active Compounds. Singapore: Springer Nature 237-283. https://doi.org/10.1007/978-981-13-7154-7_9 ![]() |
[15] |
Tasneem S, Liu B, Li B, et al. (2019) Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res 139: 126-140. https://doi.org/10.1016/j.phrs.2018.11.001 ![]() |
[16] |
Cavanagh HMA, Wilkinson JM (2002) Biological activities of lavender essential oil. Phytother Res 16: 301-308. https://doi.org/10.1002/ptr.1103 ![]() |
[17] |
Lis-Balchin MT (2012) Lavender. Handbook of Herbs and Spices. Cambridge: Woodhead Publishing 329-347. https://doi.org/10.1533/9780857095688.329 ![]() |
[18] |
Silva GL, Luft C, Lunardelli A, et al. (2015) Antioxidant, analgesic and anti-inflammatory effects of lavender essential oil. An Acad Bras Cienc 87: 1397-1408. https://doi.org/10.1590/0001-3765201520150056 ![]() |
[19] | Cardia GFE, Silva-Filho SE, Silva EL, et al. (2018) Effect of lavender (Lavandula angustifolia) essential oil on acute inflammatory response. Evid Based Complement Altern Med 2018: 1413940. https://doi.org/10.1155/2018/1413940 |
[20] |
Feixiong C, Weihua L, Yadi Z, et al. (2012) Admetsar: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 52: 3099-3105. https://doi.org/10.1021/ci300367a ![]() |
[21] |
Goel RK, Singh D, Lagunin A, et al. (2011) PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res 20: 1509-1514. https://doi.org/10.1007/s00044-010-9398-y ![]() |
[22] |
Homnan N, Thongpraditchote S, Chomnawang M, et al. (2020) In vitro anti-inflammatory effects of Thai herb essential oils. Pharm Sci Asia 47: 153-163. https://doi.org/10.29090/psa.2020.02.019.0020 ![]() |
[23] |
Kim KN, Ko YJ, Yang HM, et al. (2013) Anti-inflammatory effect of essential oil and its constituents from fingered citron (Citrus medica L. var. sarcodactylis) through blocking JNK, ERK and NF-κB signaling pathways in LPS-activated RAW 264.7 cells. Food Chem Toxicol 57: 126-131. https://doi.org/10.1016/j.fct.2013.03.017 ![]() |
[24] |
Yu L, Yan J, Sun Z (2017) D-limonene exhibits anti-inflammatory and antioxidant properties in an ulcerative colitis rat model via regulation of iNOS, COX-2, PGE2 and ERK signaling pathways. Mol Med Rep 15: 2339-2346. https://doi.org/10.3892/mmr.2017.6241 ![]() |
[25] |
Yoon WJ, Lee NH, Hyun CG (2010) Limonene suppresses lipopolysaccharide-induced production of nitric oxide, prostaglandin E2, and pro-inflammatory cytokines in RAW 264.7 macrophages. J Oleo Sci 59: 415-421. https://doi.org/10.5650/jos.59.415 ![]() |
[26] |
Sousa OV, Silvério MS, Del-Vechio-Vieira G, et al. (2008) Antinociceptive and anti-inflammatory effects of the essential oil from Eremanthus erythropappus leaves. J Pharm Pharmacol 60: 771-777. https://doi.org/10.1211/jpp.60.6.0013 ![]() |
[27] |
Ogunwande IA, Avoseh ON, Olasunkanmi KN, et al. (2019) Chemical composition, anti-nociceptive and anti-inflammatory activities of essential oil of Bougainvillea glabra. J Ethnopharmacol 232: 188-192. https://doi.org/10.1016/j.jep.2018.12.017 ![]() |
[28] |
Suh HR, Chung HJ, Park EH, et al. (2016) The effects of Chamaecyparis obtusa essential oil on pain-related behavior and expression of pro-inflammatory cytokines in carrageenan-induced arthritis in rats. Biosci Biotech Bioch 80: 203-209. https://doi.org/10.1080/09168451.2015.1075864 ![]() |
[29] |
Rufino AT, Ribeiro M, Sousa C, et al. (2015) Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. Eur J Pharmacol 750: 141-150. https://doi.org/10.1016/j.ejphar.2015.01.018 ![]() |
[30] |
Siddappa MK, Satyanarayan ND, Yarbagi M, et al. (2016) Anti-proliferative and ADMET screening of novel 3-(1 H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives. Cogent Chem 2: 1172542. https://doi.org/10.1080/23312009.2016.1172542 ![]() |
[31] |
Guimarães AC, Meireles LM, Lemos MF, et al. (2019) Antibacterial activity of terpenes and terpenoids present in essential oils. Molecules 24: 2471. https://doi.org/10.3390/molecules24132471 ![]() |
[32] |
Zengin H, Baysal AH (2014) Antibacterial and antioxidant activity of essential oil terpenes against pathogenic and spoilage-forming bacteria and cell structure-activity relationships evaluated by SEM microscopy. Molecules 19: 17773-17798. https://doi.org/10.3390/molecules191117773 ![]() |
[33] | Baccouri B, Rajhi I (2021) Potential antioxidant activity of terpenes. Terpenes and Terpenoids Recent Advances. London: IntechOpen 53-62. https://doi.org/10.5772/intechopen.96638 |
[34] |
de Cássia da Silveira e Sá R, Andrade LN, de Sousa DP (2013) A review on anti-inflammatory activity of monoterpenes. Molecules 18: 1227-1254. https://doi.org/10.3390/molecules18011227 ![]() |
[35] | Zarlaha A, Kourkoumelis N, Stanojkovic TP, et al. (2014) Cytotoxic activity of essential oil and extracts of Ocimum basilicum against human carcinoma cells. Molecular docking study of isoeugenol as a potent cox and lox inhibitor. Dig J Nanomater Biostructures 9: 907-917. |
[36] |
Refaey MS, Abouelela ME, El-Shoura EA, et al. (2022) In vitro anti-inflammatory activity of Cotula anthemoides essential oil and in silico molecular docking of its bioactives. Molecules 27: 1994. https://doi.org/10.3390/molecules27061994 ![]() |